Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | Phase
Phase 2
|
Date Added 2024-06-12 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06415851 |
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | Phase
Phase 2
|
Date Added 2024-05-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06412198 |
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Phase
Phase 1, Phase 2
|
Date Added 2024-05-14 |
Location
Massachusetts, United States
Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Adagrasib, cemiplimab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2024-03-29 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase
Phase 1
|
Date Added 2024-03-21 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Korea, Republic of Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06310564 |
TitleLow and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy | Phase
Not Applicable
|
Date Added 2024-03-15 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06300463 |
TitlePlatform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Phase
Phase 2
|
Date Added 2024-03-08 |
Location
New York, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AGEN1423, Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06302062 |
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2024-03-08 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06253520 |
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Phase
Phase 1
|
Date Added 2024-02-12 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06218914 |
TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Phase
Phase 1
|
Date Added 2024-01-23 |
Location
California, United States
Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|




